3
|
Tong S, Kaitu'u-Lino TJ, Onda K, Beard S, Hastie R, Binder NK, Cluver C, Tuohey L, Whitehead C, Brownfoot F, De Silva M, Hannan NJ. Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion. Hypertension 2015; 66:1073-81. [PMID: 26324507 DOI: 10.1161/hypertensionaha.115.05847] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Accepted: 08/06/2015] [Indexed: 12/31/2022]
Abstract
Elevated placental release of the antiangiogenic factors, soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sENG), is central to the pathophysiology of preeclampsia. It is widely accepted that heme oxygenase-1 (HO-1) is decreased in preeclamptic placenta and negatively regulates sFlt-1 and sENG production. We set out to verify these contentions. There was no difference in HO-1 mRNA or protein levels in preterm preeclamptic placentas (n=17) compared with gestationally matched controls (n=27). In silico analysis of microarray studies did not identify decreased placental HO-1 expression in preeclamptic placenta. Silencing HO-1 in primary trophoblasts did not affect sFlt-1 protein secretion after 24 or 48 hours. Silencing nuclear factor (erythroid-derived 2)-like 2 (transcription factor that upregulates HO-1) in trophoblasts also did not affect sFlt-1 secretion. Administering tin protoporphyrin IX dichloride (HO-1 inhibitor) or cobalt protoporphyrin (HO-1 inducer) into placental explants did not affect sFlt-1 or sENG secretion. Silencing HO-1 in 2 types of primary endothelial cells (human umbilical vein endothelial and uterine microvascular endothelial cells) significantly increased sFlt-1 secretion but not sENG secretion. However, HO-1 silencing selectively increased mRNA expression of sFlt-1 i13 (generically expressed sFlt-1 variant) but not of sFlt-1 e15a (sFlt-1 variant mainly expressed in placenta). Furthermore, adding tin protoporphyrin IX dichloride decreased sFlt-1, whereas adding HO-1 inducers (cobalt protoporphyrin, dimethyl fumarate, and rosiglitazone) either had no effect or increased sFlt-1 or sENG secretion (these trends are opposite to what is expected). We conclude that HO-1 expression is not decreased in preeclamptic placenta and HO-1 does not negatively regulate placental sFlt-1 and sENG secretion in placental or endothelial cells.
Collapse
Affiliation(s)
- Stephen Tong
- From the Translational Obstetrics Group, the Department of Obstetrics and Gynaecology, Mercy Hospital for Women, University of Melbourne, Heidelberg, Victoria, Australia (S.T., T.J.K.-L., K.O., S.B., R.H., N.K.B., C.C., L.T., C.W., F.B., M.D.S., N.J.H.); Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, School of Pharmacy, Tokyo, Japan (K.O.); and Department of Obstetrics and Gynaecology, Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa (C.C.).
| | - Tu'uhevaha J Kaitu'u-Lino
- From the Translational Obstetrics Group, the Department of Obstetrics and Gynaecology, Mercy Hospital for Women, University of Melbourne, Heidelberg, Victoria, Australia (S.T., T.J.K.-L., K.O., S.B., R.H., N.K.B., C.C., L.T., C.W., F.B., M.D.S., N.J.H.); Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, School of Pharmacy, Tokyo, Japan (K.O.); and Department of Obstetrics and Gynaecology, Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa (C.C.)
| | - Kenji Onda
- From the Translational Obstetrics Group, the Department of Obstetrics and Gynaecology, Mercy Hospital for Women, University of Melbourne, Heidelberg, Victoria, Australia (S.T., T.J.K.-L., K.O., S.B., R.H., N.K.B., C.C., L.T., C.W., F.B., M.D.S., N.J.H.); Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, School of Pharmacy, Tokyo, Japan (K.O.); and Department of Obstetrics and Gynaecology, Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa (C.C.)
| | - Sally Beard
- From the Translational Obstetrics Group, the Department of Obstetrics and Gynaecology, Mercy Hospital for Women, University of Melbourne, Heidelberg, Victoria, Australia (S.T., T.J.K.-L., K.O., S.B., R.H., N.K.B., C.C., L.T., C.W., F.B., M.D.S., N.J.H.); Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, School of Pharmacy, Tokyo, Japan (K.O.); and Department of Obstetrics and Gynaecology, Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa (C.C.)
| | - Roxanne Hastie
- From the Translational Obstetrics Group, the Department of Obstetrics and Gynaecology, Mercy Hospital for Women, University of Melbourne, Heidelberg, Victoria, Australia (S.T., T.J.K.-L., K.O., S.B., R.H., N.K.B., C.C., L.T., C.W., F.B., M.D.S., N.J.H.); Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, School of Pharmacy, Tokyo, Japan (K.O.); and Department of Obstetrics and Gynaecology, Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa (C.C.)
| | - Natalie K Binder
- From the Translational Obstetrics Group, the Department of Obstetrics and Gynaecology, Mercy Hospital for Women, University of Melbourne, Heidelberg, Victoria, Australia (S.T., T.J.K.-L., K.O., S.B., R.H., N.K.B., C.C., L.T., C.W., F.B., M.D.S., N.J.H.); Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, School of Pharmacy, Tokyo, Japan (K.O.); and Department of Obstetrics and Gynaecology, Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa (C.C.)
| | - Cathy Cluver
- From the Translational Obstetrics Group, the Department of Obstetrics and Gynaecology, Mercy Hospital for Women, University of Melbourne, Heidelberg, Victoria, Australia (S.T., T.J.K.-L., K.O., S.B., R.H., N.K.B., C.C., L.T., C.W., F.B., M.D.S., N.J.H.); Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, School of Pharmacy, Tokyo, Japan (K.O.); and Department of Obstetrics and Gynaecology, Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa (C.C.)
| | - Laura Tuohey
- From the Translational Obstetrics Group, the Department of Obstetrics and Gynaecology, Mercy Hospital for Women, University of Melbourne, Heidelberg, Victoria, Australia (S.T., T.J.K.-L., K.O., S.B., R.H., N.K.B., C.C., L.T., C.W., F.B., M.D.S., N.J.H.); Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, School of Pharmacy, Tokyo, Japan (K.O.); and Department of Obstetrics and Gynaecology, Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa (C.C.)
| | - Clare Whitehead
- From the Translational Obstetrics Group, the Department of Obstetrics and Gynaecology, Mercy Hospital for Women, University of Melbourne, Heidelberg, Victoria, Australia (S.T., T.J.K.-L., K.O., S.B., R.H., N.K.B., C.C., L.T., C.W., F.B., M.D.S., N.J.H.); Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, School of Pharmacy, Tokyo, Japan (K.O.); and Department of Obstetrics and Gynaecology, Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa (C.C.)
| | - Fiona Brownfoot
- From the Translational Obstetrics Group, the Department of Obstetrics and Gynaecology, Mercy Hospital for Women, University of Melbourne, Heidelberg, Victoria, Australia (S.T., T.J.K.-L., K.O., S.B., R.H., N.K.B., C.C., L.T., C.W., F.B., M.D.S., N.J.H.); Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, School of Pharmacy, Tokyo, Japan (K.O.); and Department of Obstetrics and Gynaecology, Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa (C.C.)
| | - Manarangi De Silva
- From the Translational Obstetrics Group, the Department of Obstetrics and Gynaecology, Mercy Hospital for Women, University of Melbourne, Heidelberg, Victoria, Australia (S.T., T.J.K.-L., K.O., S.B., R.H., N.K.B., C.C., L.T., C.W., F.B., M.D.S., N.J.H.); Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, School of Pharmacy, Tokyo, Japan (K.O.); and Department of Obstetrics and Gynaecology, Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa (C.C.)
| | - Natalie J Hannan
- From the Translational Obstetrics Group, the Department of Obstetrics and Gynaecology, Mercy Hospital for Women, University of Melbourne, Heidelberg, Victoria, Australia (S.T., T.J.K.-L., K.O., S.B., R.H., N.K.B., C.C., L.T., C.W., F.B., M.D.S., N.J.H.); Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, School of Pharmacy, Tokyo, Japan (K.O.); and Department of Obstetrics and Gynaecology, Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa (C.C.)
| |
Collapse
|
5
|
Velickovic I, Dalloul M, Wong KA, Bakare O, Schweis F, Garala M, Alam A, Medranda G, Lekovic J, Shuaib W, Tedjasukmana A, Little P, Hanono D, Wijetilaka R, Weedon J, Lin J, Toledano RD, Zhang M. Complement factor B activation in patients with preeclampsia. J Reprod Immunol 2015; 109:94-100. [PMID: 25604034 DOI: 10.1016/j.jri.2014.12.002] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2014] [Revised: 11/14/2014] [Accepted: 12/08/2014] [Indexed: 01/28/2023]
Abstract
Preeclampsia is a leading cause of maternal and fetal morbidity and mortality. Bb, the active fragment of complement factor B (fB), has been reported to be a predictor of preeclampsia. However, conflicting results have been found by some investigators. We hypothesized that the disagreement in findings may be due to the racial/ethnic differences among various study groups, and that fB activation is significant in women of an ethnic minority with preeclampsia. We investigated the maternal and fetal levels of Bb (the activated fB fragment) in pregnant women of an ethnic minority with or without preeclampsia. We enrolled 291 pregnant women (96% of an ethnic minority, including 78% African-American). Thirteen percent of these were diagnosed with preeclampsia. Maternal venous blood was collected from all participants together with fetal umbilical cord blood samples from 154 deliveries in the 291 women. The results were analyzed using the Mann-Whitney U test and multivariate analyses. Maternal Bb levels were significantly higher in the preeclamptic group than in the nonpreeclamptic group. Levels of Bb in fetal cord blood were similar in both groups. Subgroup analyses of African-American patients' results confirmed the study hypothesis that there would be a significant increase in Bb in the maternal blood of the preeclamptic group and no increase in Bb in the fetal cord blood of this group. These results suggest that a maternal immune response through complement fB might play a role in the development of preeclampsia, particularly in African-American patients.
Collapse
Affiliation(s)
- Ivan Velickovic
- Department of Anesthesiology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
| | - Mudar Dalloul
- Department of Obstetrics & Gynecology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
| | - Karen A Wong
- Department of Anesthesiology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
| | - Olufunke Bakare
- Department of Anesthesiology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
| | - Franz Schweis
- Department of Anesthesiology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
| | - Maya Garala
- Department of Anesthesiology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
| | - Amit Alam
- Department of Anesthesiology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
| | - Giorgio Medranda
- Department of Anesthesiology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
| | - Jovana Lekovic
- Department of Anesthesiology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
| | - Waqas Shuaib
- Department of Anesthesiology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
| | - Andreas Tedjasukmana
- Department of Anesthesiology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
| | - Perry Little
- Department of Anesthesiology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
| | - Daniel Hanono
- Department of Anesthesiology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
| | - Ruvini Wijetilaka
- Department of Anesthesiology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA; Department of Anesthesiology, Lutheran Medical Center, Brooklyn, NY 11220, USA
| | - Jeremy Weedon
- Scientific Computing Center, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
| | - Jun Lin
- Department of Anesthesiology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA; Department of Anesthesiology, University Hospital of Brooklyn at Long Island College Hospital, Brooklyn, NY 11201, USA
| | - Roulhac d'Arby Toledano
- Department of Anesthesiology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA; Department of Anesthesiology, Lutheran Medical Center, Brooklyn, NY 11220, USA
| | - Ming Zhang
- Department of Anesthesiology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA; Department of Cell Biology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA.
| |
Collapse
|